BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33289168)

  • 1. Cardiotoxicity of immune checkpoint inhibitors: An updated review.
    Behravesh S; Shomali N; Danbaran GR; Aslani S; Hemmatzadeh M; Hosseinzadeh R; Gowhari-Shabgah A; Mohammadi H
    Biotechnol Appl Biochem; 2022 Feb; 69(1):61-69. PubMed ID: 33289168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
    Liu Y; Chen Y; Zeng Z; Liu A
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
    Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
    Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.
    Zarifa A; Lopez-Mattei J; Palaskas N; Iliescu C; Durand JB; Kim PY
    Adv Exp Med Biol; 2020; 1244():277-285. PubMed ID: 32301022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
    Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
    Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors - the revolutionary cancer immunotherapy comes with a cardiotoxic price.
    Achim A; Liblik K; Gevaert S
    Trends Cardiovasc Med; 2024 Feb; 34(2):71-77. PubMed ID: 36152788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment].
    Arangalage D; Pavon AG; Hugelshofer S; Desgraz B; Tzimas G; Delyon J; Muller O; Obeid M; Ribi C; Michielin O; Özdemir BC; Monney P
    Rev Med Suisse; 2020 Jun; 16(696):1165-1168. PubMed ID: 32496706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiotoxicity danger in immunotherapy.
    Jagielska B; Ozdowska P; Gepner K; Kubala S; Siedlecki JA; Sarnowski TJ; Sarnowska E
    IUBMB Life; 2020 Jun; 72(6):1160-1167. PubMed ID: 32359132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mathematical modelling of autoimmune myocarditis and the effects of immune checkpoint inhibitors.
    van der Vegt SA; Polonchuk L; Wang K; Waters SL; Baker RE
    J Theor Biol; 2022 Mar; 537():111002. PubMed ID: 35007511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
    Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
    Baik AH; Tsai KK; Oh DY; Aras MA
    Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
    Arangalage D; Degrauwe N; Michielin O; Monney P; Özdemir BC
    Cancer Treat Rev; 2021 Nov; 100():102282. PubMed ID: 34438238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Call for attention to the scientific issues in cardiovascular adverse effects associated with immune checkpoint inhibitors].
    Zhang ZR
    Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(42):3328-3331. PubMed ID: 37963733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular toxicity of immune therapies for cancer.
    Palaskas NL; Ali HJ; Koutroumpakis E; Ganatra S; Deswal A
    BMJ; 2024 May; 385():e075859. PubMed ID: 38749554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.
    Frayberg M; Yung A; Zubiri L; Zlotoff DA; Reynolds KL
    Curr Treat Options Oncol; 2021 May; 22(6):53. PubMed ID: 34037918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management.
    Eftekhar SP; Yazdanpanah N; Rezaei N
    Expert Rev Anticancer Ther; 2021 Nov; 21(11):1211-1228. PubMed ID: 34511008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicities associated with immune checkpoint inhibitors.
    Yang S; Asnani A
    Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall.
    Piras L; Zuccanti M; Russo P; Riccio F; Agresti A; Lustri C; Dardani D; Ferrera A; Fiorentini V; Tocci G; Tini Melato G; Volpe M; Barbato E; Battistoni A
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.